Voice Technology Company ArkX Laboratories Inks European Sales Agreement With Redtree Solutions
17.11.2020 09:00:00 EET | Business Wire | Press release
ArkX Laboratories, a leading provider of advanced far-field voice-capture technology, has appointed Redtree Solutions, the largest Pan-European electronic representative in the semiconductor industry, as the exclusive sales representative for its production-ready EveryWord™ voice solution in the Europe, Middle East and Africa (EMEA) marketplace.
This announcement coincides with growing demand from Fortune 1000 companies, OEMs, and start-ups in the region who want to bring their voice-enabled smart products and devices to market. The EveryWord™ portfolio offers a production-ready path that delivers an unmatched voice experience while mitigating risk, reducing development costs, and accelerating their time-to-market.
Featuring Cirrus Logic's SoundClear™ and FlexArray™ technologies, ArkX's advanced line of production-ready voice capture solutions outperform other existing solutions in far-field voice capture and deliver a far-superior voice experience to consumers. The products are Alexa-compatible and meet or exceed all requirements for the Amazon Voice Services (AVS) qualifications. In addition to Alexa, EveryWord™ is compatible with other platforms such as Google, Siri, Cortana, AliGenie, Baidu/Kitt.ai, Tencent, and Sensory. EveryWord™ voice solutions can be customized for a company's eco-system and applied to a wide range of products, including speakers, soundbars, televisions, appliances, voice controllers, and gadgets. For smart home applications, the modules can be installed in hubs, ceilings, and in-wall.
"The ArkX EveryWord portfolio solves the toughest problems facing innovative OEMs today, including capturing voice at a greater distance, around corners, in the presence of blaring TV, and other noisy and reverberative environments without having to lower playback volume," said ArkX CEO Eric Bauswell. "EveryWord truly outperforms the performance of standard far-field voice solutions by so large a margin that consumers will never want to go back to the 'old' technology."
Covering 19 countries with more than 500 active customers, Redtree will help accelerate ArkX Labs' market penetration in the region by generating greater awareness of the company's solutions and providing on-the-ground support to ArkX Labs' expanding customer base.
"We were impressed with the innovation and superior far-field performance of the EveryWord™ solutions. It's a huge leap forward and certainly the best far-field solutions ever seen on the marketplace over our 10+ years' experience in this segment," said Steve Judge, Redtree Solutions Managing Director. "The addition of ArkX's EveryWord™ voice solutions represent a strategic addition to our electronic component portfolio that will have appeal to many of our customers operating in the smart home, broadband telecom, consumer, robotic, automotive, and industrial marketplaces."
ArkX Executive Vice President Michael Lang added, "Redtree's experience, expertise, and support structure provides the perfect fit to help us expand our reach beyond existing North American and Asian markets."
The product line offers clear performance advantages for capturing voice commands from three times the standard distance, around corners, noisy and reflective environments, and without lowering playback volume. Additionally, EveryWord™ technology provides a unique ability to identify and to suppress speech from TV or other single-point noise sources.
EveryWord™ technology does not require source-ducking for reliable interaction, provides linear, circular, square, triangular, or 3D mic array geometries, and requires fewer microphones. The technology features ultra-low power battery operation for wake-on-word, and the flexibility for placement of microphones allows for in-wall, ceiling, or dashboard solutions. The 3D mic array versus other linear beam-forming approaches enables fewer blind spots and increased performance while incorporating fewer redundant microphone arrays for coverage.
About ArkX Laboratories
ArkX Laboratories, a joint venture between product development pioneer, Surfaceink, and consumer electronics manufacturer Ark Electronics USA brings an exceptional voice experience to the marketplace. Our next generation of advanced, high-performance far-field voice capture solutions, featuring Cirrus Logic and NXP technology, are Amazon pre-qualified and production-ready. ArkX provides Fortune 1000, OEMs, and start-ups who want their own branded, voice-enabled IoT products and smart devices with the ability to reduce their development time and costs and accelerate their time-to-market while mitigating the risk. For more information, please visit www.arkxlabs.com.
About Redtree Solutions
Redtree Solutions is the largest Pan-European Representative company in the region. More than 40 people provide service, speak local languages, and cover 19 countries with more than 500 active customers. Redtree invests in next-generation technologies for the benefit of its customers and is dedicated to their success. The Redtree application team is devoted to helping customers find the most optimized architecture for your Electronic systems, with the help of their partners' solutions and expertise. Redtree is headquartered near Oxford, UK. For more information, please visit www.redtree-solutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006041/en/
Contact information
Jean-Marie Houillon, +33 (0)1 30 47 25 33
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom